Smallish UK biotech Oxford BioTherapeutics Ltd. stands to gain $370 million under a new partnership with drug giant GlaxoSmithKline plc to discover, develop and commercialize therapeutic antibodies aimed at treating primary, metastatic and recurring forms of cancer. (BioWorld Today)

WASHINGTON — While members of the Senate Finance Committee Tuesday were engaged with economists and budget and tax experts in an attempt to unravel the knotty challenges of paying for health reform, President Obama was hosting his own roundtable at the White House, where companies presented their innovative ideas that have succeeded in reducing costs. (BioWorld Today)